Non-invasive Assessment of Skeletal Muscle Loss in Cancer Patients

Status

Completed

Phases

Unknown

Study type

Observational

Source

ClinicalTrials.gov

Registry ID

NCT01015274

Enrollment

Registered

2009-11-18

Start date

2009-10-31

Completion date

Unknown

Last updated

2018-07-11

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Cachexia

Brief summary

The long-term objective of this research is to develop a non-invasive approach for early assessment of which patients are at high risk for future development of skeletal muscle atrophy. The investigators hypothesize that the rate constant for the terminal portion of the isotope decay curve following ingestion of a single oral dose of deuterated-3-methylhistidine (D-3MH) provides an accurate measure of this increased risk and that this rate constant can be measured non-invasively from timed spot urine samples.

Interventions

None listed

Study design

Observational model

COHORT

Time perspective

PROSPECTIVE

Eligibility

Sex/Gender

MALE

Age

30 Years to 75 Years

Healthy volunteers

Yes

Inclusion criteria

* Male * 30-75 years old * Body Mass Index (BMI) \<27 kg/m2

Exclusion criteria

* Uncontrolled hypertension * Glomerular filtration rate less than 60 mL/min/1.73 m2 * History of recurrent gastrointestinal bleeding * Unable or unwilling to provide informed consent * Ongoing anti-coagulant therapy

Countries

United States

Outcome results